Skip to content
AnalystLens

Teva Pharmaceutical Industries 8-K Report, Financial Results (Jan 12, 2026)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed January 12, 2026
Period End
January 11, 2026
Security
TEVA
In the record · 2016–202610-K1110-Q278-K283

TEVA filed 11 annual reports (10-K), 27 quarterly reports (10-Q) and 283 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Nov ’19Nov ’19
  2. Leadership change8-K · Nov ’22Nov ’22
  3. Leadership change8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed January 12, 2026. Cited figures are marked; the original filing is the authoritative source.

Teva Pharmaceutical Industries Ltd. furnished this Form 8-K under Item 2.02 (Results of Operations and Financial Condition) to announce its expected 2025 financial performance and to preview its outlook ahead of its presentation at the 44th Annual J.P.

Morgan Healthcare Conference on January 13, 2026. The accompanying press release (Exhibit 99.1), dated January 11, 2026, frames the presentation around the company's "Pivot to Growth" strategy, highlighting AUSTEDO, AJOVY and UZEDY as key innovative brands and a pipeline that includes olanzapine LAI, DARI (ICS/SABA), duvakitug (anti-TL1A), emrusolmin and anti-IL-15. The expected 2025 performance is presented against the company's prior outlook, with most metrics described as landing at the lower end, midpoint or higher end of their ranges, excluding duvakitug milestones.

Expected 2025 GAAP revenues are $16.8 to $17.0 billiona, adjusted EBITDA is $4.8 to $5.0 billion, diluted EPS is $2.55 to $2.65, and free cash flow is $1.6 to $1.9 billion, with net leverage of approximately 2.5x to 2.9x. The filing also states additional contributions from expected duvakitug milestones of about $500 million to revenues and about $500 million to free cash flow, along with approximately $400 million to $430 million to adjusted EBITDA. For 2026, the company guides to flat to slightly down GAAP revenues versus 2025, growing operating profit, growing adjusted EBITDA and growing free cash flow, with net leverage of approximately 2.0x to 2.2x.

Its path to 2027 targets includes low-single-digit revenue growth, a 30% operating margin, free cash flow above $2.7 billionb and net leverage below 2x. Longer-term 2030 targets include mid-single-digit revenue CAGR, operating margin above 30%, free cash flow above $3.5 billion and net leverage below 2x.

Cumulative transformation program savings are expected to be approximately $450 million to $500 millionc in 2026 and about $700 million by 2027. The release states the company is committed to disciplined capital allocation and to securing an investment-grade credit rating.

02—Key points

Key Highlights

  1. Expected 2025 GAAP revenues of $16.8 to $17.0 billion, with the lower point of the range cited, excluding duvakitug milestones; about $500 million of additional revenue contribution from expected duvakitug milestones.
  2. Expected 2025 diluted EPS of $2.55 to $2.65 (higher point of the range) and adjusted EBITDA of $4.8 to $5.0 billion (midpoint of the range).
  3. Expected 2025 free cash flow of $1.6 to $1.9 billion (higher point of the range), plus about $500 million from expected duvakitug milestones; net leverage of approximately 2.5x to 2.9x.
  4. 2026 outlook calls for flat to slightly down GAAP revenues versus 2025, with operating profit, adjusted EBITDA and free cash flow all growing versus 2025 and net leverage of approximately 2.0x to 2.2x.
  5. 2027 targets include low-single-digit revenue growth, a 30% operating margin, free cash flow above $2.7 billion and net leverage below 2x.
  6. 2030 targets include a mid-single-digit revenue CAGR, operating margin above 30%, free cash flow above $3.5 billion and net leverage below 2x.
  7. Cumulative transformation program savings are expected to reach approximately $450 million to $500 million in 2026 and about $700 million by 2027.

03—Questions

Frequently Asked Questions

  1. What did Teva expect its 2025 financial performance to be?

    Teva expects GAAP revenues of $16.8 to $17.0 billion, adjusted EBITDA of $4.8 to $5.0 billion, diluted EPS of $2.55 to $2.65, and free cash flow of $1.6 to $1.9 billion, with net leverage of approximately 2.5x to 2.9x. Most metrics are described relative to their outlook ranges, excluding duvakitug milestones.

  2. How much could duvakitug milestones add to 2025 results?

    The filing states expected additional contributions from duvakitug milestones of about $500 million to revenues, approximately $400 million to $430 million to adjusted EBITDA, about $500 million to free cash flow, and roughly 80% to 85% to operating margin, with net leverage of about 2.5x.

  3. What is Teva's outlook for 2026?

    The company expects GAAP revenues to be flat to slightly down versus 2025, with operating profit, adjusted EBITDA and free cash flow all growing versus 2025. Net leverage is expected to be approximately 2.0x to 2.2x, and cumulative transformation program savings of approximately $450 million to $500 million.

  4. What are Teva's medium-term targets?

    For 2027, Teva targets low-single-digit revenue growth, a 30% operating margin, free cash flow above $2.7 billion, and net leverage below 2x. For 2030, it targets a mid-single-digit revenue CAGR, operating margin above 30%, free cash flow above $3.5 billion, and net leverage below 2x.

04—Continue

← View all 8-K filings